Boceprevir and Ucalm (St John&Apos;s Wort)

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (340 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: classtreatednewadequatetreatment of
  Phrases that lowered it: healthycontainingalcoholdrugvolunteers
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 18.8% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 4 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 6.2% (lowers risk) · Drug's FDA history
• Collaborators: 2 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 70.9% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 16 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, digestive: Yes (raises risk) · Disease area
• Disease area, psychiatry: No (lowers risk) · Disease area
• Maximum age: 65 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) NCT01181804 · started 2010 · scored riskier than 1% of active trials completed
• Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive NCT03984825 · started 2019 · scored riskier than 4% of active trials completed
• SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat NCT02589158 · started 2015 · scored riskier than 5% of active trials completed
• A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ NCT01597648 · started 2011 · scored riskier than 2% of active trials completed
• Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet NCT02893488 · started 2016 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.